Skip to main content
. 2020 May 28;12(6):488. doi: 10.3390/pharmaceutics12060488

Figure 6.

Figure 6

Cotreatment of stigmasterol and inhibitors in ovarian cancer cells. (A,B) Western blots showed changes of PI3K and MAPK by cotreatment with stigmasterol or each inhibitor in ovarian cancer cells. Comparative graph represented the change of phosphorylation compared to the vehicle-treated control (100%) in ES2 and OV90 cells.